201 related articles for article (PubMed ID: 15325441)
21. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA;
Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.
Karlowsky JA; Draghi DC; Thornsberry C; Jones ME; Critchley IA; Sahm DF
Int J Antimicrob Agents; 2002 Aug; 20(2):76-85. PubMed ID: 12297355
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of faropenem against respiratory pathogens.
du Plessis M; Capper TP; Klugman KP
J Antimicrob Chemother; 2002 Mar; 49(3):575-7. PubMed ID: 11864964
[No Abstract] [Full Text] [Related]
24. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
25. Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
Nicolau DP
Am J Manag Care; 2004 Oct; 10(12 Suppl):S381-8. PubMed ID: 15603247
[No Abstract] [Full Text] [Related]
26. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
27. [The current epidemiologic situation and resistance of respiratory pathogens in Spain].
García de Lomas J
Med Clin (Barc); 1998 Feb; 110 Suppl 1():44-51. PubMed ID: 9717161
[No Abstract] [Full Text] [Related]
28. [The postantibiotic effect of azithromycin on respiratory pathogens].
Diculencu D; Andrews JM; Boswell FJ; Wise R
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):128-34. PubMed ID: 9455450
[TBL] [Abstract][Full Text] [Related]
29. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Biedenbach DJ; Barrett MS; Croco MA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
[TBL] [Abstract][Full Text] [Related]
30. [Antibiotic resistance: an always present problem].
Debbia EA
Recenti Prog Med; 1999 Oct; 90(10):505-9. PubMed ID: 10592734
[No Abstract] [Full Text] [Related]
31. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Jones RN; Biedenbach DJ; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):573-8. PubMed ID: 9764398
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
33. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Appelbaum PC
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
Biedenbach DJ; Jones RN; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):240-4. PubMed ID: 18353594
[TBL] [Abstract][Full Text] [Related]
35. The crisis of resistant pathogens in respiratory tract infections--use of pharmacodynamic principles.
Palavecino EL
Am J Manag Care; 2001 Jun; 7(6 Suppl):S170-7. PubMed ID: 11424585
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of ertapenem against selected respiratory pathogens.
Marchese A; Gualco L; Schito AM; Debbia EA; Schito GC
J Antimicrob Chemother; 2004 Nov; 54(5):944-51. PubMed ID: 15472001
[TBL] [Abstract][Full Text] [Related]
37. Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2005 and 2006.
Gomi K; Watanabe A; Aoki S; Kikuchi T; Fuse K; Nukiwa T; Kurokawa I; Fujimura S
Int J Antimicrob Agents; 2007 May; 29(5):586-92. PubMed ID: 17387003
[TBL] [Abstract][Full Text] [Related]
38. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
39. Activity of oral antibiotics against respiratory tract pathogens in Spain.
Calvo A; Amores R; Valero E; Fuentes F; Gómez-Lus ML; Prieto J;
Rev Esp Quimioter; 2003 Dec; 16(4):436-43. PubMed ID: 14961138
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic resistance. Epidemiology of resistance--respiratory tract infections.
Thomson CJ
J Med Microbiol; 1997 Jun; 46(6):442-5. PubMed ID: 9379469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
